医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Maxinovel Pharmaceuticals Announces the Presentation of Its Orally Active PD-1/PD-L1 Inhibitors in 2018 AACR

2018年02月27日 AM12:10
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

Maxinovel Pharmaceuticals today announces that it will present preclinical results of its orally active PD-1/PD-L1 inhibitors as a single agent or combination with Epacadostat, Celebrex, Cisplatin and CTLA-4, respectively. The presentation will be held in 2018 AACR in Chicago, USA. The details are as follows:

Title: Novel small molecule inhibitors of PD-1/PD-L1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel and Canonical Targets

Session Date and Time: Tuesday April 17, 2018 8:00am-12:00pm

Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 17

Permanent Abstract Number: 3851

About Maxinovel Pharmaceuticals, Inc:

Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005313/en/

CONTACT

Maxinovel Pharmaceuticals
Ms. Pingjing Zhang
pjzhang@maxinovel.com

同じカテゴリーの記事 

  • Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
  • HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss
  • Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
  • Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
  • エスリのテクノロジーをALS治療開発研究所が治験場所検索に採用